glucose, (beta-d)-isomer has been researched along with Heart Failure, Systolic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anker, SD; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Januzzi, JL; Packer, M; Pocock, SJ; Sattar, N; Schnee, J; Vedin, O; Verma, S; Zannad, F | 1 |
| Anker, SD; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Mahfoud, F; Ofstad, AP; Packer, M; Pocock, SJ; Ponikowski, P; Schüler, E; Wanner, C; Zannad, F | 1 |
| Chang, HY; Chang, WT; Hua, YM; Kuo, FH; Lee, MC; Liao, CT; Ou, HT; Strong, C; Tang, HJ; Toh, HS; Yang, CT | 1 |
| Carbone, S; daSilva-deAbreu, A; Lavie, CJ | 1 |
2 trial(s) available for glucose, (beta-d)-isomer and Heart Failure, Systolic
| Article | Year |
|---|---|
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure, Systolic; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Female; Glomerular Filtration Rate; Glucosides; Heart Failure, Systolic; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
3 other study(ies) available for glucose, (beta-d)-isomer and Heart Failure, Systolic
| Article | Year |
|---|---|
Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
Topics: Aged; Asia; Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Delivery of Health Care; Drug Costs; Female; Glucosides; Heart Failure, Systolic; Hospital Costs; Hospitalization; Humans; Male; Markov Chains; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2021 |
Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure, Diastolic; Heart Failure, Systolic; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.
Topics: Benzhydryl Compounds; Glucose; Glucosides; Heart Failure; Heart Failure, Systolic; Humans; Obesity; Prognosis; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2021 |